Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Director | April 28, 2011 | April 28, 2011 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date April 28, 2011 · Filed April 28, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 97,679 |
Reported balance
After 2011-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2011-04-28 · Grant · Acquired 5,500 · Balance 97,679 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,703 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby SLAT | 5,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,162 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,162 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2018 Filed Jan 3, 2018 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001237899-18-000004 · edgardoc.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 20:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001237899-17-000024 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 20:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,500 | $475.00 | $712,500.00 |
DisclosureSEC source: 0001237899-17-000024 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 05, 2017 Filed Oct 5, 2017 20:18 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,500 | $177.82 | $266,730.00 |
DisclosureSEC source: 0001237899-17-000024 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001708138-17-000008 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $500.00 | $1,500,000.00 |
DisclosureSEC source: 0001708138-17-000008 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $177.82 | $533,460.00 |
DisclosureSEC source: 0001708138-17-000008 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · derivative · entry 9 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 606 | $475.72 | $288,286.32 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 7 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 606 shares of Company stock on June 12, 2017 at prices ranging from $475.65 to $475.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $474.37 | $426,933.00 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 6 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on June 12, 2017 at prices ranging from $474.01 to $474.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $473.37 | $94,674.00 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 5 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 12, 2017 at prices ranging from $473.36 to $473.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 94 | $469.02 | $44,087.88 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,706 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 94 shares of Company stock on June 12, 2017 at prices ranging from $469.02 to $469.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $477.05 | $47,705.00 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 3 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $472.04 | $47,204.00 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $177.82 | $355,640.00 |
DisclosureSEC source: 0001708138-17-000003 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001237899-17-000016 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 3,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $450.00 | $1,350,000.00 |
DisclosureSEC source: 0001237899-17-000016 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $177.82 | $533,460.00 |
DisclosureSEC source: 0001237899-17-000016 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001237899-17-000015 · edgardoc.xml · derivative · entry 4 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 1,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $400.00 | $400,000.00 |
DisclosureSEC source: 0001237899-17-000015 · edgardoc.xml · nonDerivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,000 | $177.82 | $177,820.00 |
DisclosureSEC source: 0001237899-17-000015 · edgardoc.xml · nonDerivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000005 · edgardoc.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 28, 2011 Filed Apr 28, 2011 19:28 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-012431 · doc4.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,679 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 22, 2010 Filed Apr 26, 2010 14:09 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-010894 · doc4.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,325 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 23, 2009 Filed Apr 24, 2009 21:12 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000079 · bro2015.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,547 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 24, 2008 Filed Apr 25, 2008 17:26 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-08-000074 · bro1726.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,891 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 26, 2007 Filed Apr 30, 2007 18:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-07-000083 · bro1482.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,326 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 27, 2006 Filed Apr 28, 2006 17:08 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-06-000087 · bro1186.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,198 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 28, 2005 Filed Apr 29, 2005 16:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 3,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000078003-05-000101 · bro926.xml · derivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,690 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F4 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 28, 2005 Filed Apr 29, 2005 16:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 977 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000078003-05-000101 · bro926.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,090 Underlying: Common Stock · 977 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Annual Retainer Unit Award Plan. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 22, 2004 Filed Apr 23, 2004 16:04 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 726 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000078003-04-000096 · bro636.xml · derivative · entry 2 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,119 Underlying: Common Stock · 726 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F4 · shares: Granted pursuant to the Pfizer Inc. Annual Retainer Unit Award Plan. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 22, 2004 Filed Apr 23, 2004 16:04 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 3,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000078003-04-000096 · bro636.xml · derivative · entry 1 BROWN MICHAEL S · CIK 0001174475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,393 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.